alpha1-antichymotrypsin

(redirected from a1-antichymotrypsin)

α1-·an·ti·chy·mo·tryp·sin

(an'tē-kī'mō-trip-sin),
An inhibitor protein of the digestive protease, chymotrypsin.
References in periodicals archive ?
CEA: Carcinoembryonic antigen, VIM: Vimentin, SMA: Smooth muscle antigen, A1AT: a1-antitrypsin, A1ACT: a1-antichymotrypsin, LYS: Lysozyme, NSE: Neuron specific enolase.
Carcinosarcoma/sarcomatoid carcinoma of the urinary bladder with features of malignant fibrous histiocytoma: the role of p53 in growth of the tumor / Malign fibroz histiyositom ozellikleri tasiyan mesane karsinosarkomasi/sarkomatoid karsinomasi: Tumor gelisiminde p53'un rolu
Prostate-specific antigen in serum occurs predominantly in complex with a1-antichymotrypsin. Clin Chem 1991;37:1618-25.
Serum prostate-specific antigen complexed to a1-antichymotrypsin as an indicator of prostate cancer.
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 [degrees]C
Serum prostate specific antigen complexed to a1-antichymotrypsin as an indicator of prostate cancer.
Development of sensitive immunoassays for free and total human glandular kallikrein 2
Prostate-specific antigen and its complexes with a1-antichymotrypsin in the plasma of patients with prostatic disease.
Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-[[alpha].sub.1]-antichymotrypsin complex together with free or total PSA
A complex between prostate-specific antigen and a1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.
In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to a1-antichymotrypsin in blood samples.
Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at [Lys.sup.145]-[Lys.sup.146]
Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to a1-antichymotrypsin from serum.
Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing
a1-Antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia.
Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys 145-Lys 146 inactive PSA
Amino acid sequence at the reactive site of human a1-antichymotrypsin. J Biol Chem 1983;258:12749-52.
Analysis of free prostate-specific antigen (PSA) after chemical release from the complex with [[alpha].sub.1]-antichymotrypsin (PSA-ACT)
Immunodetectable PSA in serum is mainly bound with a1-antichymotrypsin, whereas a minor fraction is free.
Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions
PSA, a serine protease, forms complexes with serine protease inhibitors such as [alpha]2-macroglobulin and a1-antichymotrypsin (ACT) (2).
Variation in the quantitation of prostate-specific antigen in reference material: differences in commercial immunoassays
Medical browser ?
Full browser ?